Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

NICE approval for Lilly’s Verzenios is “fantastic news for thousands of women”

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

Supporting Mental Health During a Global Pandemic

Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...

Impetus Digital

- PMLiVE

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

aHUS is an ultra-rare and life-threatening disease that causes progressive injury to vital organs

- PMLiVE

NICE recommends Keytruda for colorectal cancer patients with rare mutations

Approximately 450 patients in England will now become eligible for this treatment on the NHS

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

NICE turns down bluebird bio’s gene therapy Zynteglo

Draft guidance does not recommend routine NHS funding for beta thalassaemia treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links